Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant docetaxel + 5-fluorouracil + cisplatin with prophylactic Pegteograstim in unresectable locally advanced nasal cavity/paranasal sinus SCC
KCT0003377Phase 2Not yet recruiting
- Sponsor
- GC Biopharma
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, fluorouracil, cisplatin, pegteograstim in Nasal squamous cell carcinoma (NSCC), squamous cell carcinoma of the paranasal sinuses (SNSCC), sinonasal undifferentiated carcinoma (SNUC), sponsored by GC Biopharma. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
docetaxelfluorouracilcisplatinpegteograstim
03
Conditions
Nasal squamous cell carcinoma (NSCC)squamous cell carcinoma of the paranasal sinuses (SNSCC)sinonasal undifferentiated carcinoma (SNUC)
Beyond the preview
Go deeper on KCT0003377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003377.